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Abstract
Lung fibrosis is a major cause of mortality and morbidity in
systemic sclerosis (SSc). However, its pathogenesis still needs
to be elucidated. We examined whether the alteration of certain
proteins in bronchoalveolar lavage fluid (BALF) might have a
protective or a causative role in the lung fibrogenesis process.
For this purpose we compared the BALF protein profile
obtained from nine SSc patients with lung fibrosis (SScFib+) with
that obtained from six SSc patients without pulmonary fibrosis
(SScFib-) by two-dimensional gel electrophoresis (2-DE). Only
spots and spot-trains that were consistently expressed in a
different way in the two study groups were taken into
consideration. In total, 47 spots and spot-trains, corresponding
to 30 previously identified proteins in human BALF, showed no
significant variation between SScFib+  patients and SScFib-
patients, whereas 24 spots showed a reproducible significant
variation in the two study groups. These latter spots
corresponded to 11 proteins or protein fragments, including
serum albumin fragments (13 spots), 5 previously recognized
proteins (7 spots), and 4 proteins (3 spots) that had not been
previously described in human BALF maps, namely calumenin,
cytohesin-2, cystatin SN, and mitochondrial DNA
topoisomerase 1 (mtDNA TOP1). Mass analysis did not
determine one protein-spot. The two study groups revealed a
significant difference in BALF protein composition. Whereas
levels of glutathione S-transferase P (GSTP), Cu–Zn superoxide
dismutase (SOD) and cystatin SN were downregulated in
SScFib+ patients compared with SScFib- patients, we observed a
significant upregulation of α1-acid glycoprotein, haptoglobin-α
chain, calgranulin (Cal) B, cytohesin-2, calumenin, and mtDNA
TOP1 in SScFib+ patients. Some of these proteins (GSTP, Cu–
Zn SOD, and cystatin SN) seem to be involved in mechanisms
that protect lungs against injury or inflammation, whereas others
(Cal B, cytohesin-2, and calumenin) seem to be involved in
mechanisms that drive lung fibrogenesis. Even if the 2-DE
analysis of BALF did not provide an exhaustive identification of
all BALF proteins, especially those of low molecular mass, it
allows the identification of proteins that might have a role in lung
fibrogenesis. Further longitudinal studies on larger cohorts of
patients will be necessary to assess their usefulness as
predictive markers of disease.
Introduction
The analysis of the bronchoalveolar lavage fluid (BALF) pro-
teome can potentially provide important information about
changes in protein expression and secretion during the course
of pulmonary disorders. At the moment, more than 100 human
proteins or protein isoforms have been identified in human
Anti-Scl70 = anti-topoisomerase I antibodies; BAL = bronchoalveolar lavage; BALF = bronchoalveolar lavage fluid; Cal = calgranulin; 2-DE = two-
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BALF by using two-dimensional gel electrophoresis (2-DE),
including both proteins released locally in the lung by inflam-
matory or epithelial cells and proteins derived from serum by
diffusion across the capillary–alveolar barrier [1,2]. Previous
studies showed that the protein composition of BALF was
altered in sarcoidosis, idiopathic pulmonary fibrosis, allergic
asthma, and chronic obstructive pulmonary disease [3-5]. Fur-
thermore, Rottoli and colleagues [6] recently demonstrated
that systemic sclerosis patients with pulmonary fibrosis (SSc-
Fib+) showed a BALF profile that was intermediate between
that of patients with sarcoidosis and idiopatic pulmonary fibro-
sis, despite some particularities.
Systemic sclerosis (SSc) is an autoimmune disorder of
unknown origin, characterized by an excessive deposition of
collagen and other extracellular matrix proteins on the skin as
well as multiple internal organs, alterations in microvascula-
ture, and humoral and cellular abnormalities [7]. Clinically, the
disease is very heterogeneous, ranging from limited skin
involvement with limited systemic alterations to clinical pic-
tures with diffuse skin sclerosis and severe visceral involve-
ment with fibrosis, microvascular abnormalities and
mononuclear cell infiltration of the gastrointestinal tract, lungs,
heart, and kidneys. Pulmonary involvement has emerged as
potentially the most serious visceral lesion in SSc. Alveolitis is
more commonly seen in SSc with diffuse skin sclerosis, partic-
ularly in the presence of serum anti-topoisomerase I (anti-
Scl70) antibodies, but only 15% of patients eventually reach
severe end-stage lung fibrosis [8].
Given the complexity of the pathogenesis of lung fibrosis and
the lack of biological markers that can reliably predict which
patients will evolve the disease, great interest has been shown
in these issues, also comparing cohorts of SSc patients with
or without lung involvement. The ability to identify the proteins
that are differently expressed in the lower airways of SScFib+
patients from those in SScFib- patients might provide new
insight into the disease pathogenesis and into the identifica-
tion of possible protein biomarkers of the disease's progres-
sion. With this aim, we used the 2-DE analysis to assess and
compare the protein profile of BALFs from a group of SScFib+
and SScFib- patients, respectively.
Materials and methods
Patients
The samples consisted of archived BALF samples acquired
between March 2004 and April 2005 from 15 SSc patients
who satisfied the preliminary American College of Rheumatol-
ogy criteria for disease classification [9]. All the patients were
female and non-smoker outpatients at the Rheumatology Unit
of the Policlinico San Matteo, Pavia, Italy. They all gave their
informed consent to undergo bronchoscopy, and none were
being treated with prednisone or other immunosuppressive
agents at the time of enrollment. Five patients had SSc with
limited skin involvement and 10 had SSc with diffuse skin scle-
rosis; indirect immunofluorescence on Hep-2 cells detected
the antinuclear antibodies, and the anti-Scl70 antibodies were
evaluated by enzyme-linked immunosorbent assay (Diamedix
Co., Miami, FL, USA). All the patients tested positive for anti-
nuclear antibodies, and nine had anti-Scl70 antibodies.
The diagnosis of SSc-associated lung fibrosis was based on
clinical, functional and radiographic signs. In all the cases, car-
bon monoxide transfer, forced vital capacity, chest radiogra-
phy, and high-resolution computed tomography (HRCT)
determined the respiratory involvement, which was defined as
at least a grade 1 severity on the disease severity scale for
SSc [10]. In all the cases, the same expert radiologist calcu-
lated the Kazerooni score for fibrosis as described previously
[11]. Nine patients showed a decrease of at least 20% with
regard to the expected carbon monoxide transfer or forced
vital capacity values [12]. This decrease was associated with
abnormal chest radiograph and the presence of significant
fibrosis on the HRCT scan (mean Kazerooni fibrosis score: 10
± 5 SD). These nine patients were included in the SScFib+
group. The remaining six patients, who revealed no evidence
of lung involvement either on the lung function tests or on the
HRCT scan (absence of fibrosis and/or a ground-glass pat-
tern), were included in the SScFib- group. Table 1 details the
patients' demographic, clinical, immunological and functional
characteristics.
Bronchoalveolar lavage and phenotype analysis
Bronchoalveolar lavage (BAL) was performed as described
previously [13]. To summarize briefly, the distal tip of the bron-
choscope was wedged into the middle lobe or lingular bron-
chus. A total of 150 ml of warm sterile saline solution were
instilled in 30 ml aliquots and serially recovered by gentle aspi-
ration. The first collected aliquot was used for the microscopic
and cultural examination of common bacteria and fungi, and of
direct acid-fast bacilli smears (Kinyoun method) and cultures
for mycobacteria, and for the microscopic examination of
Pneumocystis jiroveci (Gomori-Grocott silver stain). All the
other aliquots were used to assess the total and differential
cell counts (performed on cyto-centrifuged preparations with
the use of May–Grünwald–Giemsa and Papanicolaou stain-
ings) and the percentages of CD4+  and CD8+  T cells
(assessed by cytofluorimetry). Samples were immediately fil-
tered twice through gauze, then centrifuged at 1,500 r.p.m. for
10 min, and BALF samples were promptly frozen in aliquots
and stored at -80°C until used.
Two-dimensional gel electrophoresis
BALF samples were dialyzed (tubing cut-off 1 kDa) for a few
days against several changes of distilled water, in the pres-
ence of protease inhibitors (protease inhibitor cocktail; Sigma,
St Louis, MO, USA), and the protein content was assessed
(bicinchoninic acid protein assay kit; Pierce, Rockford, IL,
USA). Samples were freeze-dried and pellets were suspended
in 8 M urea, 4% w/v CHAPS, 65 mM 1,4-dithioerythritol (solu-Available online http://arthritis-research.com/content/8/6/R160
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tion A). Two-dimensional gel electrophoresis was performed
as described previously [14]. In brief, for each analytical exper-
iment the same amount (70 μg) of proteins was loaded on
immobilized pH gradient (IPG) strips (pH 3.5 to 10, 18 cm;
Amersham Biosciences, Uppsala, Sweden), which were swol-
len in solution A plus 0.8% carrier ampholytes (Ampholine™,
pH 3.5 to 10 for IEF; Amersham Biosciences) and a trace of
bromophenol blue. A larger amount of protein (1 mg) had to be
loaded for identification by mass spectrometry (MS). Rehydra-
tion was performed in the strip holder of the IPGphor system
at 20°C (Amersham Biosciences) and isoelectrofocusing was
terminated at 60 kV h. The IPG strips were equilibrated first for
12 minutes in urea/SDS/Tris buffer, and then in the same
buffer containing 2.5% (w/v) iodoacetamide. The run in the
second dimension was performed on 9 to 16.5% polyacryla-
mide linear gradient gels with a constant current of 40 mA per
gel at 10°C. The gels were stained with ammoniacal silver
nitrate or colloidal Coomassie G-250 [15].
Evaluation and protein identification
The Versadoc Imaging System Model 3000 (Bio-Rad, Rich-
mond, CA, USA) scanned the gels, which the PD QUEST 7.1
software (Bio-Rad) then analyzed. The total number of spots,
the non-matched spots and the spot parameters were meas-
ured. To detect differentially expressed protein spots in SSc-
Fib+ compared with those in SScFib- patients, the software was
instructed to create one reference map for each patient group.
The software established these maps by taking into account
only the spots that were constantly expressed in each patient
of the same group. At least two gels from each patient were
evaluated. Initially, we compared the two reference maps so as
to assess differences in spot quantity between the two study
groups. The PD QUEST 7.1 software determined the spot
quantity by formula: Spot height × π × σx × σy (where the spot
height represented the peak of the spot's Gaussian represen-
tation, and σx and σy were the SD of the spot's Gaussian dis-
tribution in the directions of the x and y axes, respectively)
normalized the value for the total protein content of each gel.
The differences between the two study groups were then con-
firmed by analysing the spot quantities observed in single
patients. On the basis of the recent guidelines for proteomics
research [16], non-matched spots and spots that differed sig-
nificantly in quantity (p < 0.05) were regarded as differentially
expressed in SScFib+ compared with SScFib- patients.
Proteins were identified by comparing the BALF maps
obtained in this study with the SWISS-2D PAGE human
plasma map [17] and published BALF maps [5,6], using
immunoblotting, matrix-assisted laser desorption/ionization
MS, and/or liquid chromatography MS/MS. For the MS analy-
sis, the selected spots, excised from Coomassie-stained gels,
were analyzed in a Voyager DE-PRO mass spectrometer
(Applied Biosystems, Foster City, CA, USA), equipped with a
reflectron analyzer and used in delayed extraction mode. Mass
signals were used for database searching with the MASCOT
peptide fingerprinting search program (Matrix Science, Bos-
ton, MA, USA). A quadrupole time-of-flight. Ultima hybrid mass
spectrometer (Micromass, Toronto, Ontario, Canada) was
Table 1
Demographic, clinical, immunological and functional characteristics of scleroderma patients
Characteristic SScFib+ SScFib-
Number 96
Age, years (mean ± SD) 55.6 ± 10.3 50.5 ± 9.6
Cutaneous involvement
Lc SSc (percentage) 1 (11.1) 4 (66.7)
Dc SSc (percentage) 8 (89.9) 2 (33.3)
Skin score (mean ± SD) 17.0 ± 8.0 10.0 ± 6.0
Autoantibodies
ANA positive (percentage) 9 (100) 6 (100)
Anti-Scl70 positive (percentage) 7 (77.7) 2 (33)
Lung function test
FVC, percentage predicted (mean ± SD) 80.9 ± 11.7a 118.7 ± 11.6
TLCO, percentage predicted (mean ± SD) 60.01 ± 12.6a 72.03 ± 13.8
Kazerooni score 10.0 ± 5 0
Skin score and Kazerooni score for fibrosis were determined as described previously [9,11]. SScFib+, systemic sclerosis patients with functional 
lung fibrosis and signs of lung fibrosis on high-resolution computed tomography; SScFib-, SSc patients with no signs and symptoms of lung 
involvement; Lc SSc, limited cutaneous SSc; Dc SSc, diffuse cutaneous SSc; ANA, antinuclear antibodies; anti-Scl70, anti-topoisomerase I 
antibodies; FVC, forced vital capacity; TLCO, carbon monoxide transfer. aDecrease more than 20% with regard to the expected TLCO or FVC 
values.Arthritis Research & Therapy    Vol 8 No 6    Fietta et al.
Page 4 of 11
(page number not for citation purposes)
used for the liquid chromatography–MS/MS analysis. The
instrument was set up in a data-dependent MS/MS mode, and
the raw MS and MS/MS spectra were elaborated with Protein-
Lynx software. The MASCOT MS/MS ion search software for
protein identification was used. These evaluations were per-
formed at CEINGE Biotecnologie Avanzate s.c. a r.l., Univer-
sity Federico II, Naples, Italy).
Statistical methods
Results are presented as mean ± SD or median and interquar-
tile range. Normally distributed variables were analyzed by a
two-tailed Student's t test. Proteomics expression data were
compared by using the Mann–Whitney U test. For all tests p
< 0.05 was regarded as significant. Analyses were performed
with PRISM 3.0 (GraphPad Software, San Diego, CA, USA).
Results
BAL was performed in 15 SSc patients, including 9 patients
with clinical, functional and HRCT signs of interstitial lung
fibrosis (SScFib+ patients) and 6 patients who had no signs
and symptoms of lung involvement (SScFib- patients). No clini-
cal or microbiological evidence of bacterial or fungal infections
was ever found in the included patients. Furthermore, the two
patient groups revealed no significant difference in total BAL
cells recovered, CD4+/CD8+ T-cell ratio, protein content, or
differential BAL cell counts, although the SScFib+ patients dis-
played a trend toward higher neutrophil and eosinophil counts
(Table 2). Neutrophil and eosinophil counts, as expected, were
significantly higher in the SScFib+  patients than in data
obtained in our laboratory from a group of healthy volunteers
[12].
BALF proteome in SScFib+ and SScFib- patients
Two-dimensional gel electrophoresis analyzed the whole pro-
tein profile of BALF from SScFib+ and SScFib- patients, to eval-
uate possible differences in protein expression between the
two states of the disease. The mean number of spots, of which
several were organized as spot-trains, in gels of BALF from
SScFib+ and SScFib- patients was 365 ± 84 and 390 ± 75,
respectively. However, only 332 and 348 of these spots were
constantly expressed in BALF from all single SScFib+ and SSc-
Fib- patients, respectively. Figure 1 shows a representative
Coomassie-stained gel map from an SScFib+ patient (Figure
1a) and an SScFib- patient (Figure 1b). By comparing the quan-
tity of 59 individual spots and 12 spot-trains, we identified 35
spots and 12 spot-trains whose quantity did not vary signifi-
cantly between SScFib+ and SScFib- patients (Mann–Whitney
U test p > 0.05). By matching these gel maps with published
two-dimensional BALF maps, we identified 30 proteins corre-
sponding to the 47 spots and spot-trains that did not vary in
quantity between the two patient groups (Table 3). Immunob-
lotting also validated the assignment of some of these pro-
teins. Furthermore, we detected 24 individual spots that
showed a reproducible, significant variation between the two
study groups. The quantity in 21 of these spots was signifi-
cantly increased, whereas the quantity in 3 spots was signifi-
cantly decreased in SScFib+ patients compared with SScFib-
patients.
Matrix-assisted laser desorption/ionization MS with or without
liquid chromatography–MS/MS analysis identified the pro-
teins corresponding to 21 spots that were constantly and sig-
nificantly expressed in a different way between the two study
groups. A comparison with published two-dimensional BALF
maps followed by immunoblotting validation identified the pro-
teins corresponding to the remaining three spots with the
aforementioned criteria (Table 4). These 24 differently
expressed spots corresponded to 11 proteins/protein frag-
ments in total: 13 spots corresponded to serum albumin frag-
ments, 7 of them corresponded to 5 previously recognized
BALF proteins (α1-acid glycoprotein (2 spots), haptoglobin-α
chain (2 spots), calgranulin (Cal) B, Cu–Zn superoxide dis-
mutase (SOD) and glutathione S-transferase P (GSTP)), and
3 spots corresponded to 4 proteins that, to our knowledge,
had not previously been described in published BALF two-
dimensional maps (calumenin and cytohesin-2 (1 spot), cysta-
Table 2
Cytology, CD4+/CD8+ T-cell ratio and protein contents of bronchoalveolar lavage samples
Parameter SScFib+ (n = 9) SScFib- (n = 6) Controls (n = 9)
Total BAL cells (105/ml) 2.05 ± 1.13 1.80 ± 0.74 2.02 ± 1.33
Macrophages (percentage) 84.97 ± 8.66 87.73 ± 5.12 85.78 ± 7.09
Lymphocytes (percentage) 8.01 ± 4.15 7.80 ± 2.63 12.33 ± 6.36
Neutrophils (percentage) 4.44 ± 4.03a 2.76 ± 1.98 1.56 ± 1.59
Eosinophils (percentage) 2.62 ± 3.66a 0.83 ± 0.60 0.33 ± 0.70
CD4+/CD8+ ratio 2.30 ± 1.02 2.14 ± 1.16 2.4 ± 0.71
Protein concentration (μg/ml) 130.44 ± 53.76 133.43 ± 32.38 ND
Results are given as mean ± SD. SScFib+, systemic sclerosis patients with functional lung fibrosis and signs of lung fibrosis on high-resolution 
computed tomography; SScFib-, SSc patients with no signs and symptoms of lung fibrosis. Control values are taken from data previously assessed 
in a group of healthy volunteers [12]. BAL, bronchoalveolar lavage; ND, not determined. ap < 0.05 compared with controls (all assessed by 
Student's t test).Available online http://arthritis-research.com/content/8/6/R160
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tin SN and a fragment of mtDNA TOP1). One protein spot was
marked as not determined because its identification gave a
score that indicated uncertain identification. SScFib+ patients
showed a significant upregulation of α1-acid glycoprotein,
haptoglobin-α chain, Cal B, calumenin, and cytohesin-2 levels
compared with SScFib- patients. Furthermore, the expression
of a fragment of mtDNA TOP1 was exclusively detectable in
SScFib+ patients, including two patients who were negative for
anti-Scl70 serum antibodies. Finally, whereas Cu–Zn SOD
was significantly downregulated, GSTP and cystatin SN were
not detectable in SScFib+ patients in contrast with SScFib-
patients.
Discussion
The pathogenesis of SSc is extremely complex, and no single
unifying hypothesis or pathogenetic mechanism can explain all
the aspects of this disease. It is therefore widely accepted that
functional alterations of several cell effectors, including fibrob-
lasts, endothelial cells, and T and B lymphocytes, are intimately
involved in the development of the clinical and pathological
manifestations of SSc [7,18,19]. Abnormalities in lung func-
tion occur in about 70% of SSc patients and currently repre-
sent the main cause of mortality in this population [7].
However, the factors that drive the severe and progressive vis-
ceral fibrosis remain mostly undetermined. Unlike the recent
pathogenetic hypothesis for idiopathic interstitial lung fibrosis,
which assigns only a marginal role to inflammation, fibrogene-
sis in SSc-related lung involvement is generally thought to be
the result of a complex series of interstitial immunoinflamma-
tory reactions [20]. The persistent and unregulated activation
of genes that encode various collagen and other extracellular
matrix proteins is regarded as a crucial pathogenetic event
[21,22]. Furthermore, an alteration in the production of pro-
inflammatory and/or pro-fibrotic cytokines and chemokines,
growth factors (in particular transforming growth factor-β), and
signaling molecules also seems to have a relevant role in fibro-
genesis [23,24]. The identification of proteins that are differ-
ently expressed in the airways of SScFib+ patients compared
with patients with no signs or symptoms of lung involvement
may cast light on the pathogenetic mechanism of the disease
and may thereby indicate protein biomarkers that are useful for
the diagnosis of lung involvement, for the monitoring of SSc
progression, and for the identification of possible new thera-
peutic targets. In this context, the use of 2-DE and the map-
ping of BALF seem highly interesting.
Our results demonstrated that quantitative and qualitative dif-
ferences can be found between patients with SSc-associated
lung fibrosis and patients with SSc with no signs or symptoms
of lung involvement. At least 24 well-defined spots showed
significant and reproducible variations in relative abundance
between the two patient groups. Some of these spots corre-
sponded to previously described BALF proteins and protein
fragments, namely α1-acid glycoprotein, GSTP, Cu–Zn SOD,
haptoglobin-α chain, and calgranulin B, whereas 4 of the pro-
teins found had not previously been described in published
two-dimensional BALF maps, namely cytohesin-2, calumenin,
cystatin SN, and human mtDNA TOP1 fragment. In SScFib+
patients, GSTP and cystatin SN were below the detection
limit, whereas Cu–Zn SOD was downregulated. In contrast,
α1-acid glycoprotein, calumenin, cytohesin-2, haptoglobin-α
chain, and calgranulin B were significantly upregulated, and
the expression of mtDNA TOP1 was observed only in SScFib+
patients.
On the basis of these preliminary results, we can infer that 2-
DE analysis of BALF can provide useful insight into the under-
standing of mechanisms involved in lung fibrogenesis through
the identification of proteins that are deregulated in SSc-asso-
ciated lung fibrosis. However, our results, as well as those of
previous studies, clearly indicated that 2-DE analysis did not
provide an exhaustive identification of all proteins that can be
present in BALF, especially those of low molecular mass such
as cytokines, chemokines, growth factors, and signaling mole-
cules. Because these molecules are thought to be relevant to
the pathogenesis of SSc-associated lung fibrosis, a combina-
tion of 2-DE analysis and proteomic approaches that specifi-
cally address the identification of these factors is necessary for
the assessment of the whole protein pattern of BALF. Despite
these considerations, most of the proteins we found differently
regulated between SScFib+ patients and SScFib- patients could
have a role in the development of lung fibrosis, whereby some
of them are involved in the mechanisms that protect against
lung injury or inflammation whereas others are involved in the
mechanisms that drive fibroproliferation.
Oxidative stress is believed to be important in the pathogene-
sis of lung damage and in the development of lung fibrosis
[25]. Among various enzymatic and non-enzymatic mecha-
nisms that protect cells and tissues from oxidants [26,27], glu-
tathione transferases [28] and SODs [29] are among such
mechanisms that are thought to have a key protective role,
especially in the lung. High levels of extracellular SODs are
thought to have a protective role for lung matrix [29]. Recently,
Tourkina and colleagues [30] demonstrated a deficiency in
GSTP1 in scleroderma lung fibroblasts. The observation that
GSTP and Cu–Zn SOD levels are severely downregulated in
BALF from SScFib+ patients is in line with these findings, and
confirms the relevance of these molecules as a defense tool
for the lung against oxidant-induced damage and/or fibropro-
liferation.
Moreover, in BALF from SScFib+ patients, we did not detect
levels of cystatin SN, which was, in contrast, well represented
in SScFib- patients. Cystatin SN is a secreted protein, which
belongs to SD-type or type-2 cystatins [31], which are potent
inhibitors of CA clan mammalian cysteine peptidases. Intracel-
lularly, these enzymes participate in normal protein turnover, in
antigen and protein processing, and in apoptosis, whereas
extracellularly they are involved in the inhibition of the proteo-Arthritis Research & Therapy    Vol 8 No 6    Fietta et al.
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Figure 1
Representative Coomassie-stained gels of bronchoalveolar lavage fluid Representative Coomassie-stained gels of bronchoalveolar lavage fluid. Samples shown were taken from a systemic sclerosis patient with lung fibro-
sis (SScFib+) (a) and a systemic sclerosis patient without lung fibrosis (SScFib-) (b). Analyzed spots are marked with a number and the corresponding 
identified proteins are listed in Tables 3 and 4. Proteins whose expression was significantly different between SScFib+ patients and SScFib- patients 
are also indicated by name.Available online http://arthritis-research.com/content/8/6/R160
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lytic cascade [32]. The direct inhibition of endogenous and
exogenous cysteine peptidases is the only function described
so far for cystatin SN, suggesting that its function is to protect
tissues against injury induced by these enzymes. However,
recent results obtained with other type-2 cystatins seem to
suggest a broader spectrum of activities, including the upreg-
ulation of IL-6 by human gingival fibroblasts, interferon-γ
expression in CD4+ T cells [33,34], and the involvement in the
differentiation and maturation of human dendritic cells [35].
Furthermore, we found an upregulation of at least six proteins
in BALF from SScFib+ patients: haptoglobin-α chain, α1-acid
Table 3
Proteins whose quantity in BALF did not significantly vary between SScFib+ and SScFib- patients
Spot no. Protein Identification method
11 β glycoprotein GM
2H e m o p e x i n GM
3 Transferrin GM
4A l b u m i n GM
5 Ig heavy chain α GM
6 Vitamin D-binding protein GM
7 α1-antitrypsin GM, Ab
8 α1-antichymotrypsin GM, Ab
9 α1-HS-glycoprotein GM
10 Leucin-rich α2-glycoprotein GM
11 Fibrinogen γ A chain GM, Ab
12 Ig heavy chain γ GM
14 Haptoglobulin 1β chain GM
15 Pulmonary surfactant-associated protein A GM
16 Apolipoprotein A1 GM, Ab
17 Ig light chain κ, λ GM, Ab
18 Serum retinol-binding protein GM
20 Transthyretin GM, Ab
21 Immunoglobulin-binding factor GM
22 Calgranulin A GM
23 Hemoglobin β chain GM
24 ERP60 (protein disulfide isomerase) GM, Ab
25 α1-antitrypsin (fragment) GM, Ab
26 Ig J chain GM
27 C-reactive protein GM
28–30 Apolipoprotein A1 (fragment) GM, Ab
31 Calcyphosine GM
32 TCTP (translationally controlled tumor protein) GM
33 ATP synthase δ chain mitochondrial GM
34 L-FABP (liver fatty acid-binding protein) GM
Spot quantity was assessed by PDQUEST 7.1 software on two BALF gel maps of individual SScFib+ (n = 9) and SScFib- (n = 6) patients. Spot 
quantity between SScFib+ and SScFib- patients did not differ significantly (Mann–Whitney U test, p > 0.05). Spot no. refers to the annotations in 
Figure 1. BALF, bronchoalveolar lavage fluid; SScFib+, systemic sclerosis patients with functional lung fibrosis and signs of lung fibrosis on high-
resolution computed tomography; SScFib-, SSc patients with no signs and symptoms of lung fibrosis; GM, gel matching with plasma two-
dimensional gel electrophoresis database from Swiss-PROT [17] and published two-dimensional gel electrophoresis BALF maps [5,6]; Ab, 
immunoblotting.Arthritis Research & Therapy    Vol 8 No 6    Fietta et al.
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glycoprotein, calumenin, cytohesin-2, Cal B, and mtDNA
TOP1.
Haptoglobin and α1-acid glycoprotein are positive acute-
phase proteins, whose plasma concentrations increase during
inflammation [36]. The increased levels of both proteins in
BALF from SScFib+ patients is likely to originate from the pas-
sive diffusion from plasma, as a result of the increased perme-
ability of the air–blood barrier during the course of fibrosing
alveolitis.
Calumenin is a member of the CREC family [37] that is
secreted into the medium of cultured cells including fibrob-
lasts [38] and early melanosomes [39]. Intracellularly, calu-
menin has a chaperone function in several Ca2+-regulated
processes, but extracellularly its function is not yet fully under-
stood. Vorum and colleagues found that calumenin binds to
the serum amyloid P component, suggesting that it is involved
in the formation of amyloid deposits in different tissues [40].
Coppinger and colleagues recently described the presence of
calumenin in platelets and its release on platelet activation, as
well as the protein's presence in human atherosclerotic
lesions [41], therefore suggesting a possible role of this pro-
tein in leading to vascular injury through the promotion of plate-
let adhesion, fibrinogenesis, and intravascular thrombus
deposition. Taking into account that a crucial pathogenetic
step in SSc involves injury to microvasculature [19,20], it is
possible to infer that calumenin could have a role in taking
such an injury to lung level.
Cytohesin-2 is a member of a family of cytoplasmic signaling
proteins [42], which may move from the cytosol to the plasma
membrane after cell stimulation [43]. Although its biological
function is mostly unknown, a recent study demonstrated that
cytohesin-2 is an activator of the mitogen-activated protein
(MAP) kinase signaling pathway [44]. Because MAP kinases
are activator signals for lung fibroblasts [23], we suggest that
cytohesin-2 might participate in the development and/or pro-
gression of lung fibrosis in SSc patients through the activation
of the MAP kinase signaling pathways in lung fibroblasts. This
hypothesis needs to be verified with further experimental
observations.
Calgranulin B is an S100 protein that is unique together with
Cal A in its myeloid-specific expression profile and in its abun-
dance in neutrophils [45]. Increased levels of Cal B are
present in the bronchial secretion of patients with chronic
inflammatory disease, and these levels may induce the produc-
Table 4
BALF proteins whose regulation in SScFib+ and SScFib- patients is different
Spot no. Median (IQR) spot quantity Protein or fragment MW (kDa) pI AC Identification 
method
SScFib+ SScFib- p
13 328.0 (256.5–482.5) 86.0 (68.6–110.4) 0.0003 α1-acid glycoprotein (orosomucoid) 23.5 4.93 P02763 GM (plasma, 
BALF), Ab
19 7.9 (5.6–9.6) 28.2 (24.5–32.6) Cu–Zn superoxide dismutase 15.8 5.70 P00441 GM (plasma, 
BALF), Ab
35 343.0 (328.5–664.0) 168.0 (131.5–267.0) 0.0041 Serum albumina 69.4 5.92 P02768 MS
36 96.6 (68.9–127.6) 24.4 (17.2–64.5) 0.0012 Calgranulin B (S100A9; MRP14) 13.2 5.71 P06702 MS, GM (plasma, 
BALF)
37 53.3 (47.4–72.1) 11.1 (8.0–22.9) 0.0001 Haptoglobin (Hp2) α chaina 15.9 5.57 P00738 MS, LC, GM 
(plasma, BALF)
38 Not expressed 32.0 (29.5–39.0) Glutathione S transferase P 23.2 5.44 P09211 MS, GM (plasma, 
BALF)
39 59.1 (50.8–73.1) 14.8 (9.4–19.6) 0.0014 Cytohesin-2a,b 46.5 5.43 Q99418 MS, LC MS, LC
Calumenina,b 37.1 4.47 O43852 MS, LC MS, LC
40 29.2 (25.5–30.8) Not expressed Mitochondrial DNA topoisomerase 1a,b 69.8 9.46 Q969P6 MS, LC
41 Not expressed 45.5 (32.2–58.9) Cystatin SNb 16.3 6.82 P01037 MS, LC
42 Not expressed 37.7 (34.0–41.0) Not determined - - - (MS, LC)
Spot quantity values were measured on two BALF gel maps of individual SScFib+ (n = 9) and SScFib- (n = 6) patients by PDQUEST 7.1 software. 
Results are expressed as median and interquartile range (IQR). Spot no. refers to the annotations in Figure 1; p values were calculated with the 
Mann–Whitney U test. BALF, bronchoalveolar lavage fluid; SScFib+, systemic sclerosis patients with functional lung fibrosis and signs of lung 
fibrosis on high-resolution computed tomography; SScFib-, SSc patients with no signs and symptoms of lung fibrosis; MW, theoretical average 
molecular mass; pI, isoelectric point; AC, accession number from the Swiss-PROT 2DPAGE database [17]; GM, gel matching with plasma two-
dimensional gel electrophoresis database from Swiss-PROT [17] and published BALF two-dimensional gel electrophoresis maps [5,6]; Ab, 
immunoblotting; MS, matrix-assisted laser desorption/ionization mass spectrometry analysis; LC, liquid chromatography–tandem mass 
spectrometry analysis. aFragments. bProteins not previously described in published BALF two-dimensional gel electrophoresis maps.Available online http://arthritis-research.com/content/8/6/R160
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tion of IL-8 by airway epithelial cells [46]. Furthermore, Vie-
mann and colleagues demonstrated that the expression of Cal
B and Cal A correlates with the inflammatory activity in sys-
temic vasculitis, thereby confirming the role of these proteins
in inflammatory reactions of endothelia [47]. Although the gen-
eral consensus is that the Cal B function depends mainly on
heterodimer formation (Cal B–Cal A), several studies have
demonstrated that the monomer is also a potent stimulator of
neutrophils and is involved in the recruitment of leukocytes to
the site of inflammation through the regulation of adhesion and
the extravasion of neutrophils [45,48]. Furthermore, recom-
binant Cal B and its homodimer stimulate the proliferation of
rat fibroblasts, suggesting that this protein might also function
as a mitogen for fibroblasts in chronic inflammation [49]. On
the basis of these observations, Cal B could have a role in
SSc-associated lung fibrosis through several pathways,
including amplifying the inflammatory process by inducing the
extravasion of neutrophils and the production of IL-8, inducing
an inflammatory reaction in the endothelia, and/or stimulating
lung fibroblast proliferation.
Finally, we found that a fragment of mtDNA TOP1 was detect-
able only in BALF from patients with interstitial lung fibrosis,
including in two SScFib+ patients who were negative for serum
anti-Scl70 antibodies. This protein fragment was never
observed in BALF from SScFib-  patients, including in two
patients with positive anti-Scl70 antibodies. A common 13-
exon motif and a similar amino-acid sequence characterize
genes for mitochondrial and nuclear DNA TOP1, except for
the N-terminal domain, which in mtDNA TOP1 contains a mito-
chondrial localization sequence instead of the nuclear localiza-
tion signal [50]. Although we demonstrated that the presence
of detectable levels of mtDNA TOP1 was a constant and par-
ticular feature of SScFib+ patients, we did not fully ascertain the
antigenic role of this protein fragment and its relation with the
development of lung fibrosis. Because autoantibodies against
DNA TOP1 are strongly correlated with interstitial pulmonary
involvement in SSc [51], further studies are warranted to
assess the role and the frequency of this antigenic target in
BALF.
Conclusion
On the basis of these preliminary results we believe that the
comparative analysis of BALF proteome from SScFib+ and
SScFib- patients by 2-DE might provide a useful insight into
some relevant steps of lung fibrogenesis. SSc-associated lung
Figure 2
Hypothetical role of some disregulated BALf proteins in mechanisms driving SSc-related lung fibrosis Hypothetical role of some disregulated BALf proteins in mechanisms driving SSc-related lung fibrosis. Inflammation is thought to be the main mech-
anism driving lung fibrosis in scleroderma patients. In this complex inflammatory process several pathways are involved, including the activation of T 
cells and epithelial cells, the secretion of pro-inflammatory cytokines and growth factors, and fibroblast proliferation. Furthermore, products from the 
coagulation cascade and oxidative stress may contribute to fibrogenesis. The upregulation of calgranulin B (Cal B), cytohesin-2 and calumenin might 
favor inflammation and fibrogenesis, whereas the downmodulation of the protective factors glutathione S-transferase P (GSTP), Cu–Zn superoxide 
dismutase (SOD) and cystatin SN may amplify tissue injury and inflammation. MMP, matrix metalloproteinases; TIMP, tissue inhibitor of matrix metal-
loproteinases; ROS, reactive oxygen species; RNS, reactive nitrogen species; O2
-, superoxide; H2O2, hydrogen peroxide; NO, nitric oxide; SScFib+, 
systemic sclerosis patients with lung fibrosis; SScFib-, systemic sclerosis patients without lung fibrosis.Arthritis Research & Therapy    Vol 8 No 6    Fietta et al.
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fibrosis is a multifaceted process involving the activation of T
cells and epithelial cells, the secretion of pro-inflammatory
cytokines and growth factors, and fibroproliferation (Figure 2).
In addition, several factors, including activation of the coagula-
tion cascade and oxidative stress, are thought to influence the
development of lung fibrosis. At least six proteins that were dif-
ferently regulated in BALF from SScFib+ patients and in BALF
from SScFib- patients might have a role in the pathogenesis of
SSc-associated interstitial lung disease. As shown in Figure 2,
the upregulation of Cal B, cytohesin-2, and calumenin in BALF
from SScFib+ patients could further promote the synthesis of
pro-inflammatory cytokines, the influx of inflammatory cells,
and fibrinogenesis, whereas the downregulation of GSTP,
Cu–Zn SOD and cystatin SN could favor vascular and lung tis-
sue injury through the impairment of mechanisms that protect
against oxidants and cysteine peptidases. However, further
animal and human studies will be necessary both to assess the
actual role of each of these factors in the development of SSc-
associated lung fibrosis and to determine whether these fac-
tors are relevant as disease biomarkers, and if so which ones.
Conclusions from these studies could enable us to predict
which patients will develop progressive pulmonary fibrosis.
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